News

An increase in extensively drug-resistant Shigella infections prompted the CDC to release a health advisory for this major cause of bacterial diarrhea.

A booster dose of mRNA COVID-19 vaccination during pregnancy increases protection of infants from infection and related hospitalization.

This fungal infection is an example of either being a treatable ailment or one that can cause severe disease and death depending on access to diagnostic and treatment resources.

Investigators looked at people living with HIV (PLWH) and the impact of this form of medication on potential cardiovascular events.

“The biggest take-home message is to treat early,” says remdesivir investigator Mark Thrun, MD.

The Lucira COVID-19 & Flu Test is a single-use at-home test kit that provides results from self-collected nasal swab samples in roughly 30 minutes.

Here's a recap of our most newsworthy coverage of the CROI 2023 conference.

The federal agency is advising restaurants, retailers, and consumers against consuming raw oysters from this Canadian province.

"This case gives uncomfortable insight into a gap in early detection of infections in immunocompromised, high-risk patient populations. "

A new report shows these providers are playing a larger role in vaccine administration, but without federal legislation codifying PREP, half the US states could determine not to continue this path for pharmacists and take away this now vital responsibility.

Remdesivir reduces COVID-19 mortality, in hospitalized patients who both did and did not require oxygen.

At the CROI conference, AELIX Therapeutics announced positive topline results for a phase 2a clinical trial.

"We made a mistake," said Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP. "We needed to have a 3-dose primary series and not call these booster shots.”

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.

Despite effective vaccines and other prevention and treatment modalities, hepatitis B remains a global health challenge. “It’s not for the lack of available tools,” says professor and hepatologist H. Nina Kim, MD, MSc.

Carbapenem-resistant Enterobacterales present considerable treatment challenges. Recent cumulative evidence supports preference for therapies.

“Patients deserve more than just viral suppression,” said Harmony Garges, MD, chief medical officer of ViiV Healthcare.

The federal agency set a Prescription Drug User Fee Act (PDUFA) action date of August 2023.

A researcher who presented at CROI discusses this prolonged and debilitating condition.

A clinician presenting at CROI discusses the phenomenon and offers insights and considerations for treating patients who are dealing with this.

The unidentified German man cleared the virus after hematopoietic stem cell transplantation (HSCT), and seems to have eliminated the HIV reservoir, which would be further along than the first two HIV-free patients who underwent the same procedure.

Results reported at CROI showed that 2 cohorts of the ongoing, phase 3 DELIVER study that this form of PrEP modality posed no differences in pregnancy and infant outcomes.

“We should test everybody,” said Charles Béguelin, noting that the vast majority of hepatitis D infections go undetected.

“One size never fits all,” says hepatologist Anna Suk-Fong Lok, MD, emphasizing the need to tailor hepatitis B treatment to fit the patient.

Inequities can include access to care issues that run from prevention to acute treatment. Addressing such issues can lead to better outcomes.

A clinician offers insights on the initial conversations around learning to treat a chronic disease and the importance behind getting patients started down the right treatment path in the early days following a diagnosis.

With evolving weather patterns, the natural habitat of ticks is expanding, and more people are becoming susceptible to them.

Although fecal microbiota, live-jslm (Rebyota; RBX2660) is the first fecal microbiota product approved by the FDA, there are other microbiota-based agents in the pipeline.

The agency accepted 2 Supplemental New Drug Applications (sNDA) related to 2 different transplant populations.

Both undertreatment and overtreatment were common in this cohort of penicillin-allergic pregnant women with Group B Streptococcus (GBS).